Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CNCR Range Cancer Therapeutics ETF

交易中 10-12 13:49:33 EDT

9.02

+0.00

0.00%

最高9.02	最低9.02	成交量0.00
今开9.02	昨收9.02	日振幅0.00%
总市值704.29万	流通市值704.29万	总股本78.08万
成交额0.00	换手率0.00%	流通股本78.08万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1791827373502,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"交易中","change":0,"latestTime":"10-12 13:49:33 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"requestUrl":"/m/hq/s/CNCR","defaultTab":"news","newsList":[{"id":"2673802030","title":"光遗传学斩获2026年诺奖 哪些药企有布局？进展如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673802030","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673802030?lang=zh_cn&edition=full","pubTime":"2026-10-06 08:46","pubTimestamp":1791247560,"startTime":"0","endTime":"0","summary":"【光遗传学斩获2026年诺奖 哪些药企有布局？进展如何？】当地时间10月5日，瑞典卡罗琳医学院宣布，将2026年诺贝尔生理学或医学奖授予美国科学家卡尔·戴塞罗思、德国科学家彼得·黑格曼和格奥尔格·内格尔，以表彰他们在光门控离子通道和光遗传学方面的发现。随着诺贝尔奖光环的加持，光遗传学这一赛道有望在医药行业引发新的热潮。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202610063888722240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610063888722240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["CNCR","BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672727481","title":"英国研究推进阿尔茨海默病基因疗法开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2672727481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672727481?lang=zh_cn&edition=full","pubTime":"2026-10-04 16:07","pubTimestamp":1791101275,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224513","title":"港股异动 | 君实生物(01877)涨超4% 与美杰医疗达成战略合作 探索肿瘤治疗“多模态药械联用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224513","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224513?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:42","pubTimestamp":1790736130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超4%，截至发稿，涨4.03%，报19.09港元，成交额2326.84万港元。消息面上，据君实生物官微消息，公司宣布与美杰医疗于近日正式签署战略合作协议，双方将围绕“多模态热物理免疫调控平台技术与药物联合临床研究、新药靶点探索”等核心方向展开全方位战略合作，引领肿瘤治疗迈向“多模态药械联用”的新时代。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4585","BK1515","LU0329678170.USD","CNCR","CANC","KCAI","BK4588","LU2488822045.USD","BK1209","159891","VXUS","LU0737861772.HKD","BK1161","LU0329678337.USD","06078","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671921710","title":"UniQure在美上市股票下跌40%，此前该公司亨廷顿病基因疗法在研究中未能显著延缓疾病进展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671921710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671921710?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:32","pubTimestamp":1790688723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671167972","title":"UniQure在美上市股票盘前下跌68%，此前该公司披露其亨廷顿舞蹈症基因疗法的早期至中期研究未达预期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671167972","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671167972?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:22","pubTimestamp":1790680978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234718","title":"辉瑞（PFE）拟于2026年ESMO大会公布45项研究数据 推进下一代肿瘤治疗管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234718","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670234718?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:51","pubTimestamp":1790596274,"startTime":"0","endTime":"0","summary":"金吾财讯 | 辉瑞公司 宣布，将在2026年10月23日至27日于西班牙马德里举行的欧洲肿瘤内科学会大会上展示45项研究摘要，涵盖11场口头报告。本次发布的数据重点聚焦乳腺癌、泌尿生殖系统肿瘤及肺癌领域，旨在强化已上市药物的循证依据，同时展示后期管线中的突破性进展。3）Tivunatamig：展示联合化疗治疗一线PD-L1表达NSCLC的2期更新数据，并计划开展与PADCEV联合治疗转移性尿路上皮癌的3期试验。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306551","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0737861772.HKD","OZEM","BK1583","LU1894683348.USD","LU0321505439.SGD","BK4585","LU0170899867.USD","LU0306806265.USD","LU0225771236.USD","BK4581","LU0329678170.USD","SG9999001176.SGD","IE00B3T34201.USD","BK4568","LU0289739699.SGD","LU0058720904.USD","LU0456855351.SGD","CANC","IE00BLSP4452.SGD","BK4588","BK4599","IE00B19Z3B42.SGD","LU0868494617.USD","LU1057294990.SGD","BK4007","SG9999001176.USD","LU1066051498.USD","LU0306807586.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999002232.USD","SG9999002224.SGD","BK4592","BK4550","LU0985481810.HKD","PFE","06078","LU1066053197.SGD","LU0234572021.USD","SGXZ57979304.SGD","CNCR","IE0002270589.USD","IE00BLSP4239.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU2488822045.USD","LU0225284248.USD","BK1209","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670162224","title":"基因疗法后期研发企业ADARx Pharmaceuticals Inc. 正式公布调高规模的首次公开募股定价，成功募得","url":"https://stock-news.laohu8.com/highlight/detail?id=2670162224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670162224?lang=zh_cn&edition=full","pubTime":"2026-09-25 07:50","pubTimestamp":1790293846,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR","LQPE","QQQS","SPCK","IPO","PEVC","ACSG","BCSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668720991","title":"美国食品药品监督管理局：批准首款用于治疗A型桑菲利波综合征儿科患者的基因疗法。","url":"https://stock-news.laohu8.com/highlight/detail?id=2668720991","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668720991?lang=zh_cn&edition=full","pubTime":"2026-09-18 02:36","pubTimestamp":1789670163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533800","title":"天价基因疗法药物中国降价140万元后，终于有患者用了","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666533800?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:27","pubTimestamp":1788956872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432080","title":"当“毛孩子”老去，5万肿瘤治疗清单催生宠物抗癌险","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432080","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665432080?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:48","pubTimestamp":1788864480,"startTime":"0","endTime":"0","summary":"“这激发我们着手研发国内首款萌宠抗癌保险。”宠物抗癌险背后的经济账此前，赵先生给旺财投保了一份宠物险，但是单次赔偿限额仅有1500元。李爽说，肿瘤、肾病等老年高发疾病的诊疗负担，正成为养宠家庭绕不开的问题。保险公司需要进行广泛的数据分析与精算，以确定不同类型犬猫高发肿瘤诊疗理赔范畴，并确保整体理赔风险可控。李爽坦言，众安保险正计划以宠物肿瘤诊断为支点，持续完善覆盖宠物全生命周期的保障体系。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-08/doc-inircmeu9366925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","06078","CNCR","CANC","LU0329678170.USD","LU0329678337.USD","BK1583","LU0737861772.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800188","title":"诺华：出现死亡病例，暂停自身免疫细胞疗法相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800188?lang=zh_cn&edition=full","pubTime":"2026-09-01 12:21","pubTimestamp":1788236460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4578","LU0211331839.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4007","LU0208291251.USD","NVS","IE00B4R5TH58.HKD","IE0009355771.USD","CNCR","IE00BFTCPJ56.SGD","SYNB","PPH","IE00B2B36J28.USD","BK4585","MEDX","IE0002141913.USD","LU0070302665.USD","BK4588","IE00BJT1NW94.SGD","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663267320","title":"拜耳旗下AskBio完成2期心力衰竭基因疗法试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2663267320","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663267320?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:28","pubTimestamp":1788143322,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012684","title":"中国首款血友病基因疗法被退货，天价药支付困局如何破解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012684","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012684?lang=zh_cn&edition=full","pubTime":"2026-08-29 15:25","pubTimestamp":1787988312,"startTime":"0","endTime":"0","summary":"武田与信念医药终止三年合作，上市逾一年仍未开出首张处方。近日，武田中国与信念医药发布联合声明，宣布双方关于血友病B基因疗法波哌达可基注射液（商品名：信玖凝?）的商业化合作已于8月2日正式终止。这意味着，这桩缔结于2023年10月的独家商业化合作，在存续不足三年后宣告终结。据悉，波哌达可基是中国首个获批上市的血友病B基因治疗药物，也是全国首款获批的基因治疗产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608293859274280.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608293859274280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244441","title":"【券商聚焦】中信建投：肿瘤mRNA疫苗开创肿瘤治疗新范式，国内企业加速追赶","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244441","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661244441?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:19","pubTimestamp":1787534349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，随着Moderna个性化肿瘤mRNA疫苗临床III期取得积极结果，mRNA肿瘤疫苗正朝着商业化阶段迈进，市场空间有望逐步打开。mRNA肿瘤疫苗与ICIs联用有望开创肿瘤治疗的新范式。分类来看，个性化肿瘤疫苗具有潜在更优的治疗效果，虽然生产成本较高，但也有更大的定价空间，而通用型疫苗凭规模化生产和较低成本，有望覆盖更广泛的患者群体。AI有望赋能多个环节，加速mRNA肿瘤疫苗的迭代升级。目前国内肿瘤mRNA疫苗研发正加速追赶，未来有望实现差异化突破，相关企业及产业链公司有望受益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989097","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","LU0737861772.HKD","CNCR","CANC","BK1583","601066","MRNX","MRNY","BK0276","LU0329678170.USD","06078","BK1209","LU2488822045.USD","LU0329678337.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661991241","title":"中信建投：肿瘤mRNA疫苗开创肿瘤治疗新范式 国内企业加速追赶","url":"https://stock-news.laohu8.com/highlight/detail?id=2661991241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661991241?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:26","pubTimestamp":1787531164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","CANC","MRNY","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656875551","title":"FDA授予Xellsmart帕金森病现货型细胞疗法快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656875551?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。　　2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4588","SYNB","BK4585","WDNA","CNCR","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://loncarfunds.com/about-cncr/","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.006537},{"month":2,"riseRate":0.454545,"avgChangeRate":0.008222},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.035928},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.005206},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.002971},{"month":6,"riseRate":0.454545,"avgChangeRate":0.004127},{"month":7,"riseRate":0.636364,"avgChangeRate":0.014964},{"month":8,"riseRate":0.363636,"avgChangeRate":0.002754},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.006126},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.055198},{"month":11,"riseRate":0.545455,"avgChangeRate":0.063822},{"month":12,"riseRate":0.090909,"avgChangeRate":-0.039193}],"exchange":"NASDAQ","name":"Range Cancer Therapeutics ETF","nameEN":"Range Cancer Therapeutics ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Range Cancer Therapeutics ETF(CNCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Range Cancer Therapeutics ETF,CNCR,Range Cancer Therapeutics ETF股票,Range Cancer Therapeutics ETF股票老虎,Range Cancer Therapeutics ETF股票老虎国际,Range Cancer Therapeutics ETF行情,Range Cancer Therapeutics ETF股票行情,Range Cancer Therapeutics ETF股价,Range Cancer Therapeutics ETF股市,Range Cancer Therapeutics ETF股票价格,Range Cancer Therapeutics ETF股票交易,Range Cancer Therapeutics ETF股票购买,Range Cancer Therapeutics ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Range Cancer Therapeutics ETF(CNCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Range Cancer Therapeutics ETF(CNCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}